- Home
- MNKD vs HRMY Comparison
MNKD vs HRMY Comparison
Compare MNKD & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MNKD
- HRMY
- Stock Information
- Founded
- MNKD 1991
- HRMY 2017
- Country
- MNKD United States
- HRMY United States
- Employees
- MNKD N/A
- HRMY N/A
- Industry
- MNKD Biotechnology: Pharmaceutical Preparations
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- MNKD Health Care
- HRMY Health Care
- Exchange
- MNKD Nasdaq
- HRMY Nasdaq
- Market Cap
- MNKD 1.7B
- HRMY 1.5B
- IPO Year
- MNKD 2004
- HRMY 2020
- Fundamental
- Price
- MNKD $5.00
- HRMY $34.02
- Analyst Decision
- MNKD Buy
- HRMY Strong Buy
- Analyst Count
- MNKD 6
- HRMY 9
- Target Price
- MNKD $10.25
- HRMY $50.44
- AVG Volume (30 Days)
- MNKD 4.3M
- HRMY 928.1K
- Earning Date
- MNKD 11-05-2025
- HRMY 11-04-2025
- Dividend Yield
- MNKD N/A
- HRMY N/A
- EPS Growth
- MNKD 23.47
- HRMY 50.44
- EPS
- MNKD 0.10
- HRMY 3.17
- Revenue
- MNKD $313,787,000.00
- HRMY $825,944,000.00
- Revenue This Year
- MNKD $14.78
- HRMY $20.68
- Revenue Next Year
- MNKD $19.36
- HRMY $15.93
- P/E Ratio
- MNKD $50.82
- HRMY $10.72
- Revenue Growth
- MNKD 17.43
- HRMY 21.13
- 52 Week Low
- MNKD $3.38
- HRMY $25.52
- 52 Week High
- MNKD $7.07
- HRMY $40.93
- Technical
- Relative Strength Index (RSI)
- MNKD 39.71
- HRMY 72.12
- Support Level
- MNKD $4.95
- HRMY $33.39
- Resistance Level
- MNKD $6.24
- HRMY $34.35
- Average True Range (ATR)
- MNKD 0.29
- HRMY 1.23
- MACD
- MNKD -0.08
- HRMY 0.53
- Stochastic Oscillator
- MNKD 4.26
- HRMY 89.22
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.